Kura Oncology Inc

{ "date": [ "202612", "202712", "202812", "202912", "203012" ], "revenue_estimate": [ 92.39, 187.21, 246.55, 363.12, 934.18 ], "ebit_estimate": [ -327.32, -265.8, -211.52, -105.89, 229.52 ], "ebitda_estimate": [ -339.9, -273.42, -260.74, -248, null ], "net_income_estimate": [ -315.14, -251.58, -202.98, -36.94, 217.48 ], "per_share_eps_estimate": [ -3.34, -2.67, -2.07, -0.96, 0.28 ], "eps_nri_estimate": [ -3.54, -2.62, -2.03, -0.25, 2.46 ], "dividend_estimate": [ null, null, null, null, null ], "book_value_per_share_estimate": [ -1.18, -4.06, -4.28, null, null ], "pretax_income_estimate": [ -312.49, -257.66, -230.95, 3.94, 361.9 ], "operating_cash_flow_per_share_estimate": [ -3.35, -2.43, -2.1, 6.6, 19.16 ], "roa_estimate": [ -71.1, -69.9, -85.4, 49.3, 51.3 ], "roe_estimate": [ -360.52, 104.6, 63.09, 101.2, 62.2 ], "gross_margin_estimate": [ 97.45, 94.05, 89.21, 82.03, 76.85 ], "operating_cash_flow_estimate": [ -296.55, -215.32, -186.08, 584.83, 1697.77 ], "pettm_estimate": [ 0, 0, 0, 0, 41.15 ], "long_term_growth_rate_mean": 15.23, "long_term_revenue_growth_rate_mean": "58.30", "future_per_share_eps_estimate_growth": 14.12, "future_eps_nri_estimate_growth": 15.23, "future_revenue_estimate_growth": 58.3, "future_ebit_estimate_growth": 12.13, "future_ebitda_estimate_growth": 6.43, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": 11.09, "future_pretax_income_estimate_growth": 7.25, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": -28.11, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": -3.68, "future_operating_cash_flow_per_share_estimate_growth": null }

{ "date": [ "202606", "202609", "202612", "202703", "202706", "202709", "202712" ], "revenue_estimate": [ 21.3, 24.65, 27.7, 41.93, 47.14, 52.23, 57.53 ], "ebit_estimate": [ -81.34, -82.19, -80.46, -68.47, -64.45, -62.76, -60.41 ], "ebitda_estimate": [ -82.18, -84.58, -86.64, null, null, null, null ], "net_income_estimate": [ -78, -79.21, -77.76, -66.68, -62.97, -61.56, -59.41 ], "per_share_eps_estimate": [ -0.89, -0.86, -0.79, -0.85, -0.81, -0.81, -0.66 ], "eps_nri_estimate": [ -0.89, -0.9, -0.87, -0.72, -0.7, -0.69, -0.61 ], "dividend_estimate": [ null, null, null, null, null, null, null ], "book_value_per_share_estimate": [ null, null, null, null, null, null, null ], "pretax_income_estimate": [ -80.42, -82.51, -81.07, -75.8, -76.3, -78.6, -80.9 ], "operating_cash_flow_per_share_estimate": [ -0.87, -0.89, -0.7, null, null, null, null ], "roa_estimate": [ -15.9, -19.4, -14.3, null, null, null, null ], "roe_estimate": [ -264.88, -51.75, -395.85, null, null, null, null ], "gross_margin_estimate": [ 96.82, 95.75, 95.18, null, null, null, null ], "operating_cash_flow_estimate": [ -77.09, -78.42, -61.58, null, null, null, null ], "pettm_estimate": [ 0, 0, 0, 0, null, null, null ], "long_term_growth_rate_mean": 15.23, "long_term_revenue_growth_rate_mean": "58.30", "future_per_share_eps_estimate_growth": 14.12, "future_eps_nri_estimate_growth": 15.23, "future_revenue_estimate_growth": 58.3, "future_ebit_estimate_growth": 12.13, "future_ebitda_estimate_growth": 6.43, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": 11.09, "future_pretax_income_estimate_growth": 7.25, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": -28.11, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": -3.68, "future_operating_cash_flow_per_share_estimate_growth": null }